These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 28365223)

  • 1. Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: Suggested strategies tailored to an integrated evaluation of different risk profiles.
    Patti G; Rubboli A
    Eur J Intern Med; 2017 Jun; 41():e10-e11. PubMed ID: 28365223
    [No Abstract]   [Full Text] [Related]  

  • 2. Dual Antithrombotic Therapy in Atrial Fibrillation Patients undergoing Percutaneous Coronary Angioplasty: The Impact of Bleeding Risk Score on Outcome.
    Aznaouridis K; Tselegkidi ME; Kanakakis I; Alexopoulos D
    Thromb Haemost; 2021 Jun; 121(6):845-847. PubMed ID: 33378785
    [No Abstract]   [Full Text] [Related]  

  • 3. Bleeding complications of triple antithrombotic therapy after percutaneous coronary interventions.
    Faza NN; Mentias A; Parashar A; Chaudhury P; Barakat AF; Agarwal S; Wayangankar S; Ellis SG; Murat Tuzcu E; Kapadia SR
    Catheter Cardiovasc Interv; 2017 Feb; 89(2):E64-E74. PubMed ID: 27220088
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Triple antithrombotic therapy for atrial fibrillation and coronary stents.
    Shmyr D; Van der Merwe V; Yakiwchuk E; Barry A; Kosar L
    Can Fam Physician; 2017 May; 63(5):375-381. PubMed ID: 28500198
    [No Abstract]   [Full Text] [Related]  

  • 5. [Optimal antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention with stenting: the real question nowadays is...].
    Rubboli A; Ricci Lucchi G; Vecchio S
    G Ital Cardiol (Rome); 2019 Jun; 20(6):396. PubMed ID: 31184327
    [No Abstract]   [Full Text] [Related]  

  • 6. Increased major bleeding complications related to triple antithrombotic therapy usage in patients with atrial fibrillation undergoing percutaneous coronary artery stenting.
    Manzano-Fernández S; Pastor FJ; Marín F; Cambronero F; Caro C; Pascual-Figal DA; Garrido IP; Pinar E; Valdés M; Lip GYH
    Chest; 2008 Sep; 134(3):559-567. PubMed ID: 18641090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Triple antithrombotic therapy versus dual antiplatelet therapy in patients with atrial fibrillation undergoing drug-eluting stent implantation.
    Kang DO; Yu CW; Kim HD; Cho JY; Joo HJ; Choi RK; Park JS; Lee HJ; Kim JS; Park JH; Hong SJ; Lim DS
    Coron Artery Dis; 2015 Aug; 26(5):372-80. PubMed ID: 25768244
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antithrombotic therapy and outcomes after ICD implantation in patients with atrial fibrillation and coronary artery disease: an analysis from the National Cardiovascular Data Registry (NCDR)®.
    Ghanbari H; Nallamothu BK; Wang Y; Curtis JP
    J Am Heart Assoc; 2015 Jan; 4(2):. PubMed ID: 25637345
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Should we recommend oral anticoagulation therapy in patients with atrial fibrillation undergoing coronary artery stenting with a high HAS-BLED bleeding risk score?
    Ruiz-Nodar JM; Marín F; Roldán V; Valencia J; Manzano-Fernández S; Caballero L; Hurtado JA; Sogorb F; Valdés M; Lip GY
    Circ Cardiovasc Interv; 2012 Aug; 5(4):459-66. PubMed ID: 22787018
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antithrombotic therapy in anticoagulated patients with atrial fibrillation presenting with acute coronary syndromes and/or undergoing percutaneous coronary intervention/stenting.
    Wrigley BJ; Tapp LD; Shantsila E; Lip GY
    Pol Arch Med Wewn; 2010 Jul; 120(7-8):290-3. PubMed ID: 20693960
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The management of patients with atrial fibrillation undergoing percutaneous coronary intervention with stent implantation: in-hospital-data from the Atrial Fibrillation undergoing Coronary Artery Stenting study.
    Schlitt A; Rubboli A; Lip GY; Lahtela H; Valencia J; Karjalainen PP; Weber M; Laine M; Kirchhof P; Niemelä M; Vikman S; Buerke M; Airaksinen KE;
    Catheter Cardiovasc Interv; 2013 Dec; 82(7):E864-70. PubMed ID: 23765437
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antithrombotic management and type of stent in atrial fibrillation patients undergoing percutaneous coronary intervention.
    Ruiz-Nodar JM; Marín F; Lip GY
    Rev Esp Cardiol (Engl Ed); 2013 Jan; 66(1):12-6. PubMed ID: 23098580
    [No Abstract]   [Full Text] [Related]  

  • 13. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary intervention/ stenting.
    Lip GY; Huber K; Andreotti F; Arnesen H; Airaksinen KJ; Cuisset T; Kirchhof P; Marín F;
    Thromb Haemost; 2010 Jan; 103(1):13-28. PubMed ID: 20062939
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergic impact of oral anticoagulation control and renal function in determining major adverse events in atrial fibrillation patients undergoing percutaneous coronary intervention: insights from the AFCAS registry.
    Proietti M; Airaksinen KEJ; Rubboli A; Schlitt A; Kiviniemi T; Karjalainen PP; Lip GYH;
    Clin Res Cardiol; 2017 Jun; 106(6):420-427. PubMed ID: 28078448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antithrombotic therapy after coronary stenting in patients with nonvalvular atrial fibrillation.
    Ho KW; Ivanov J; Freixa X; Overgaard CB; Osten MD; Ing D; Horlick E; Mackie K; Seidelin PH; Džavík V
    Can J Cardiol; 2013 Feb; 29(2):213-8. PubMed ID: 23089528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reducing the cost of managing patients with atrial fibrillation undergoing percutaneous coronary intervention with stenting.
    Mehran R; Vogel B; Levy P
    J Cardiol; 2021 Jan; 77(1):93-99. PubMed ID: 32859453
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antithrombotic management of atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing coronary stenting: executive summary--a Consensus Document of the European Society of Cardiology Working Group on Thrombosis, endorsed by the European Heart Rhythm Association (EHRA) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI).
    Lip GY; Huber K; Andreotti F; Arnesen H; Airaksinen JK; Cuisset T; Kirchhof P; Marín F;
    Eur Heart J; 2010 Jun; 31(11):1311-8. PubMed ID: 20447945
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is triple antithrombotic therapy, or rather its duration and composition, the true culprit for the excess of bleeding events observed in patients with atrial fibrillation undergoing coronary intervention?
    Gragnano F; Calabrò P; Valgimigli M
    Eur Heart J; 2019 Jan; 40(2):216-217. PubMed ID: 30395219
    [No Abstract]   [Full Text] [Related]  

  • 19. Oral antithrombotic therapy in atrial fibrillation associated with acute or chronic coronary artery disease.
    Cairns JA; McMurtry MS
    Can J Cardiol; 2013 Jul; 29(7 Suppl):S60-70. PubMed ID: 23790600
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bivalirudin versus heparin plus a glycoprotein IIb/IIIa inhibitor in patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention after clopidogrel pretreatment: pooled analysis from the ACUITY and ISAR-REACT 4 trials.
    Ndrepepa G; Neumann FJ; Deliargyris EN; Mehran R; Mehilli J; Ferenc M; Schulz S; Schömig A; Kastrati A; Stone GW
    Circ Cardiovasc Interv; 2012 Oct; 5(5):705-12. PubMed ID: 23048052
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.